Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gilbert

Showing results (761-770 of 869) with videos related to

Pageof 87
Sort By:
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
The Journal of Infectious Diseases|February 16, 2017
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy TrialHolly E Janes, Kristen W Cohen, Nicole Frahm, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Pageof 87

Showing results (761-770 of 869) with videos related to

Sort By:
Pageof 87
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
The Journal of Infectious Diseases|February 16, 2017
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy TrialHolly E Janes, Kristen W Cohen, Nicole Frahm, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Pageof 87